← Leaderboards
Mukesh K. Nyati
University Of Michigan At Ann Arbor
$3,056,630
Attributed
$4,612,320
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $761.8K · FY2009–24$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,612,320 · 2
By mechanism
R01$4,612,320 · 2
Top collaborators
- Theodore S Lawrence8 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Theodore S Lawrence$30,022,406
- Jacques Eduardo Nor$18,171,241
- Thomas E. Carey$14,226,111
- Joel A Swanson$14,149,138
- Daniel G. Remick$12,614,334
Others in their field
Top investigators on “Xenograft Procedure”
- David Heimbrook · Leidos Biomedical Research, Inc.$97,763,818
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,381,339
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Peter J Houghton · University Of Texas Hlth Science Center$20,565,889
- Connie Suders · Leidos Biomedical Research, Inc.$19,812,417
- David H Sachs · Columbia University Health Sciences$18,932,200
Research focus
Xenograft ProcedureProteinsEpidermal Growth Factor ReceptorDosePhosphotransferasesTumorResponseToxic EffectDesignCancer Cell LineTreatment ProtocolsSchedulePre-ClinicalTreatment ResponseIn VitroFutureIn VivoPharmacodynamicsRegimenChemotherapyCellsCell SurvivalCell LineProtein Expression
Grant awards (13)
Development of a first-in-class mEGFR dimerization inhibitor$398,262
R01 · FY2024 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$351,000
R01 · FY2024 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$410,837
R01 · FY2023 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$351,000
R01 · FY2023 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$410,837
R01 · FY2022 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$351,000
R01 · FY2022 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$419,222
R01 · FY2021 · CA · contact PI
Development of a first-in-class mEGFR dimerization inhibitor$419,222
R01 · FY2020 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy in Head and Neck Cancer$280,746
R01 · FY2013 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy in Head and Neck Cancer$300,132
R01 · FY2012 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy in Head and Neck Cancer$301,648
R01 · FY2011 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy in Head and Neck Cancer$312,239
R01 · FY2010 · CA · contact PI
Integration of EGFR Inhibitors with Radiochemotherapy in Head and Neck Cancer$306,175
R01 · FY2009 · CA · contact PI